Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Trientine Tetrahydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 15,629Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Orphalan announces NMPA™s approval of its trientine tetrahydrochloride product
    Orphalan announces NMPA™s approval of its trientine tetrahydrochloride product

    18 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/18/2811263/0/en/Orphalan-announces-China-NMPA-s-approval-of-its-trientine-tetrahydrochloride-product-for-the-treatment-of-Wilson-disease.html

    GLOBENEWSWIRE
    18 Jan 2024
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Trientine Tetrahydrochloride
    FDA Confirms Paragraph IV Patent Litigation for Trientine Tetrahydrochloride

    08 Aug 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-trientine-tetrahydrochloride-49602.pdf

    FDA
    08 Aug 2023
    Share Share
    PANTHERx® Rare Announces Release of CUVRIOR to Treat Wilson Disease
    PANTHERx® Rare Announces Release of CUVRIOR to Treat Wilson Disease

    19 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pantherx-rare-announces-release-of-cuvrior-trientine-tetrahydrochloride-to-treat-wilson-disease-301802534.html

    PR NEWSWIRE
    19 Apr 2023
    Share Share